Vitae Pharmaceuticals plans to price initial public offering of stock

Stifel and BMO Capital are bookrunners; JMP, Wedbush PacGrow to assist

By Devika Patel

Knoxville, Tenn., Aug. 12 – Vitae Pharmaceuticals, Inc. will conduct an initial public offering of common stock with a 30-day greenshoe option, according to a Form S-1 filed Tuesday with the Securities and Exchange Commission.

Stifel and BMO Capital Markets are the joint bookrunning managers. JMP Securities and Wedbush PacGrow Life Sciences are the co-managers.

Proceeds will be used for clinical trials, drug discovery, debt maintenance, working capital and other general corporate purposes.

The clinical-stage biotechnology company is based in Fort Washington, Pa. The company intends to list its common stock on the Nasdaq under the symbol “VTAE.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.